

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



RECEIVED

JUN 01 2001

#8
S&B
PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gabriele MULTHOFF

Serial No.: 09/646,835

Filed: 11 January 2001

For: NEW USE OF HSP70 PROTEIN

Patent Art Unit: 1642

Examiner: B. Tedeschi

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**


BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

In reply to the Notice To Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed 23 March 2001, copy attached hereto, to which the Examiner set a 30-day period for response, attached hereto is a CRF of the Sequence Listing, a paper copy of the Sequence Listing and the requisite Statement.

Further, Applicants petition for a one (1) month extension of time under 37 C.F.R. § 1.136 to extend the time for response, thereby, from 22 April 2001 to **22 May 2001**. A check for \$55.00 is provided herewith, to cover said extension. However, the Commissioner is authorized to charge Deposit Account No. 18-2220 should any additional fees be triggered by the instant submission.

Respectfully submitted,


Dean H. Nakamura
Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036-2680
(202) 659-9076
Dated: 22 May 2001

BEST AVAILABLE COPY



Notice to Comply	Application No.	Applicant(s)
	09/646835 Examiner B. Tedeschi	MULTHOFF, G. Art Unit 1646
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES		
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).		
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):		
<input checked="" type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).		
<input checked="" type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
<input checked="" type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
<input type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
<input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
<input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
<input type="checkbox"/> 7. Other: Sequence Identifiers Required for specified bases		
Applicant Must Provide:		
<input checked="" type="checkbox"/> An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".		
<input checked="" type="checkbox"/> An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.		
<input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
For questions regarding compliance to these requirements, please contact:		
For Rules Interpretation, call (703) 308-4216		
For CRF Submission Help, call (703) 308-4212		
PatentIn Software Program Support		
Technical Assistance.....703-287-0200		
To Purchase PatentIn Software.....703-306-2600		
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY		

PATENT

40740

RECEIVED

JUN 01 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of: :
Gabriele MULTHOFF : Patent Art Unit: 1642
Serial No.: 09/646,835 : Examiner: B. Tedeschi
Filed: 11 January 2001 :
For: NEW USE OF HSP70 PROTEIN :


STATEMENT ACCOMPANYING REPLY UNDER 37 CFR 1.821(f) AND (g)

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

In accordance with 37 CFR 1.821 (f) and (g), the undersigned hereby states that there are no substantive differences between the information recorded in computer readable form and that submitted in the written sequence listing, further, said information provided therein does not include new matter which goes beyond the application as filed.

Respectfully submitted,



Dean H. Nakamura
Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036-2680
(202) 659-9076
Dated: 22 May 2001

BEST AVAILABLE COPY

RECEIVED WD GAU 1642
MAY 29 2001

TECH CENTER 1600/2900

PATENT

RECEIVE

JUN 01 2001

TECH CENTER 1600/2

40740

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gabriele MULTHOFF

Serial No.: 09/646,835

Filed: 11 January 2001

For: NEW USE OF HSP70 PROTEIN



Group Art Unit: 1642

Examiner: B. Tedeschi

BOX SEQUENCE

Assistant Commissioner for Patents

Washington, D.C. 20231

1. BASIC FILING FEE

Fee Description	Large Entity	Small Entity
Utility Filing Fee	<input type="checkbox"/> \$710.00	<input type="checkbox"/> \$355.00
Design Filing Fee	<input type="checkbox"/> \$320.00	<input type="checkbox"/> \$160.00
Plant Filing Fee	<input type="checkbox"/> \$490.00	<input type="checkbox"/> \$245.00
Reissue Filing Fee	<input type="checkbox"/> \$710.00	<input type="checkbox"/> \$355.00
Provisional Filing Fee	<input type="checkbox"/> \$150.00	<input type="checkbox"/> \$ 75.00
SUBTOTAL	\$	\$

2. EXTRA CLAIM FEES

TOTAL CLAIMS	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	<u>SMALL ENTITY</u>		<u>OTHER THAN A SMALL ENTITY</u>	
			RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	-	=	x 9 = \$		x 18 = \$	
05/25/2001	TSUBS9ER00000005	09646835	x 40 = \$		x 80 = \$	
01 FC:215	<input type="checkbox"/> FIRST PRESENTATION OF MULT. DEP. CLAIM			+ 135 = \$	+ 270 = \$	
			TOTAL	\$	TOTAL	\$

SUBTOTAL \$ \$

3. EXTENSION OF TIME

Fee Description	Large Entity	Small Entity
<input type="checkbox"/> Is Not Required		
<input checked="" type="checkbox"/> One-Month Extension	<input type="checkbox"/> \$ 110.00	<input checked="" type="checkbox"/> \$ 55.00
<input type="checkbox"/> Two-Month Extension	<input type="checkbox"/> \$ 390.00	<input type="checkbox"/> \$195.00
<input type="checkbox"/> Three-Month Extension	<input type="checkbox"/> \$ 890.00	<input type="checkbox"/> \$445.00
<input type="checkbox"/> Four-Month Extension	<input type="checkbox"/> \$1,390.00	<input type="checkbox"/> \$695.00
<input type="checkbox"/> Five-Month Extension	<input type="checkbox"/> \$1,890.00	<input type="checkbox"/> \$945.00

SUBTOTAL \$ **\$55.00**

4. ADDITIONAL FEES

Fee Description	Large Entity	Small Entity
<input type="checkbox"/> Notice of Appeal	<input type="checkbox"/> \$ 310.00	<input type="checkbox"/> \$155.00
<input type="checkbox"/> Utility Issue Fee (or Reissue)	<input type="checkbox"/> \$1,240.00	<input type="checkbox"/> \$620.00
<input type="checkbox"/> Petitions to the Commissioner	<input type="checkbox"/> \$ 130.00	<input type="checkbox"/> \$130.00
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> \$ 180.00	<input type="checkbox"/> \$180.00
<input type="checkbox"/> Request for Continued Examination	<input type="checkbox"/> \$ 710.00	<input type="checkbox"/> \$355.00
<input type="checkbox"/> Other	<input type="checkbox"/> \$	<input type="checkbox"/> \$
SUBTOTAL	\$	\$
TOTAL FEES DUE	\$	\$55.00

5. METHOD OF PAYMENT

Payment Enclosed:

- Check
- Money Order
- Credit Card
- Other
- Deposit Account No. 18-2220.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 18-2220. A duplicate copy of this sheet is attached.

Any additional excess claim fees under 37 C.F.R. § 1.16.

Any additional patent application processing fees under 37 C.F.R. § 1.17.

Applicant claims small entity status.
(See 37 CFR 1.27)

Respectfully submitted,

Dean H. Nakamura
Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036
(202) 659-9076

Dated: 22 May 2001